Experimental regenerative medicine shows potential to restore bone in an animal

Bone loss is a part of aging that compromises quality of life and movement in many older people, but regenerative treatments to improve their health and well-being have been limited. Now, a study led by pioneering Lankenau Institute for Medical Research (LIMR) scientist Ellen Heber-Katz, PhD, has demonstrated the ability of an experimental regenerative medicine developed in her lab to restore bone in an animal.

The preclinical study focused on a model of periodontal disease, which causes gum and bone loss that lead to tooth loss. In older individuals, the disease not only causes pain and discomfort but is the most common cause of tooth loss, affecting 30–60% of adults. However, study results showed that time release of the experimental drug, called 1,4-DPCA, fully restored diseased gums and the surrounding jaw bone, completely preventing tooth loss. Findings were published in November by the Heber-Katz team at LIMR, part of Main Line Health, in the journal Frontiers in Dental Medicine.

Development of this experimental drug represents one of the most cutting-edge research directions LIMR has driven in the 21st century. In going beyond the uncertainties of stem cell treatments, this study also offers the first preclinical proof of concept for an off-the-shelf drug that could dramatically improve the health span of an individual by regenerating bone. It also for the first time suggests the potential anti-aging uses for this drug treatment as far as broadening how it can be used to instruct perfect healing by the body."

George Prendergast, President and CEO of the Lankenau Institute for Medical Research

The periodontal disease treatment is one branch of Heber-Katz's research in regenerative medicine, a field that she pioneered in a shocking new direction in the mid-1990s. That's when she discovered a strain of laboratory mice that disproved the scientific assumption that only starfish and amphibians like salamanders were capable of healing wounds in a way that looked as if the injury never occurred.

"The results of this study are as powerful as we could have anticipated," said Heber-Katz, the Daniel B. and Florence E. Green Endowed Chair in Regenerative Medicine Research. "The restoration of significant amounts of lost bone and tissue was complete. I'm optimistic that this drug will move forward and eventually be used to prevent tooth loss in patients suffering from periodontal disease-;one of the many ways we think it could be useful."

Immunology eBook

Compilation of the top interviews, articles, and news in the last year.
Download a free copy

The drug 1,4-DPCA works by inhibiting a molecule that blocks production of a master molecule called hypoxia-inducible factor-1 (HIF-1a), a key component that is part of the body's healing response. By temporarily elevating HIF-1a, the drug shifts a tissue's metabolic state toward one used in early fetal development, where perfect healing without scarring is possible. Heber-Katz came to LIMR, an organization with expertise in early drug discovery and development, to advance work on compounds like 1,4-DPCA to activate HIF-1a. The work was based on her earlier biological research on how tissue regeneration can be stimulated during the body's healing response to an injury.

Among Heber-Katz's fellow researchers were LIMR faculty members Azamat Aslanukov, PhD, and Kamila Bedelbaeva, MD, PhD. Other collaborating researchers were from the University of Pennsylvania School of Dental Medicine and UC Berkeley.

Heber-Katz has two related patent-pending products that are nearing the stage of human testing:

  • Medicines composed of 1,4-DPCA or related compounds that are formulated as topical or injectable hydrogels. These formulations are used to promote skin healing or restore skin integrity, including tissue damaged by natural aging. Chronic wounds often do not heal for older people
  • Sutures infused with 1,4-DPCA to prevent scarring during the healing of surgical wounds

Heber-Katz has received funding from the National Institute of Dental and Craniofacial Research for nearly 80% of the direct research costs of her program, totaling $2.7 million. The remainder is financed by governmental (Department of Defense) and non-governmental resources.

Source:

Lankenau Institute for Medical Research (LIMR)

Journal reference:

Zebrowitz, E., et al. (2022) Prolyl-hydroxylase inhibitor-induced regeneration of alveolar bone and soft tissue in a mouse model of periodontitis through metabolic reprogramming. Frontiers in Dental Medicine. doi.org/10.3389/fdmed.2022.992722.

Posted in: Drug Discovery & Pharmaceuticals | Cell Biology

Tags: Aging, Arthritis, Bone, Cancer, Cardiovascular Disease, Cell, Chronic, Craniofacial, Diabetes, Drug Discovery, Hypoxia, Laboratory, Medical Research, Medicine, Molecule, Next Generation, Pain, Periodontal Disease, Preclinical, Research, Skin, Technology

Comments (0)

Source: Read Full Article